Progress in SARS-CoV-2 Vaccines
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 136
Special Issue Editor
Special Issue Information
Dear Colleagues,
The coronavirus disease 2019 (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. Therefore, it is important to further develop the COVID-19 vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, many challenges persist, including improving COVID-19 vaccines and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which largely abrogates the neutralizing effects of therapeutic antibodies. In this Special Issue, we hope to improve understanding surrounding the ongoing development efforts for different types of COVID-19 vaccines and therapeutics, including small molecule and potential antibody drugs. Furthermore, manuscripts that focus on clinical trials supporting the development and progress of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 infection are also considered for publication.
Dr. Po-Jen Hsiao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- SARS-CoV-2
- therapeutics
- mRNA vaccines
- vaccine development
- small molecule antiviral drugs
- neutralizing antibodies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
